Back
Sep 30
Education

EDU 42 - The Role of Radiotherapy in Modern Treatment of Endometrial Cancer - The Great Debate

12:45pm - 02:00pm PT
Gynecological Cancer

MODERATOR(S)

Matthew Harkenrider, MD - Loyola University Medical Center

session DESCRIPTION

This will be a debate with one moderator and two teams. The moderator will provide ground rules and background of the current landscape of endometrial cancer including ASTRO Consensus Guidelines, disparities, molecular risk stratification, 2023 FIGO and ongoing trials (RAINBO, PORTEC 4a, etc.). Debate Team 1 will argue for systemic therapy "I have not failed. Ive just found 10,000 ways that wont work." ~ No Radiation Therapy via Thomas Edison. Team 1 will review data to support systemic therapy including PORTEC 3 and GOG 258, recent immunotherapy trials, and why locoregional control may not matter with salvage therapy options. Team 2 will argue for RT with "The Reports of My Death have been Greatly Exaggerated" ~ Radiation Therapy via Mark Twain. Team 2 will review the locoregional benefit of RT, benefit of RT in subgroups through molecular analysis of PORTEC3, role of HypoFx (SPARTACUS), address questions about sequencing, dose/Fx, volume, and safety of RT with IO. The Great Debate will finish with closing arguments from each team regarding "what is the future optimal treatment" and summary of key considerations for treatment decision making by the moderator.

learning objectives

  1. Describe current standard of care and key data supporting adjuvant treatment of endometrial cancer including systemic therapy and radiation.
  2. Explain considerations for adjuvant treatment including a framework for making recommendations.

Credits

AMA PRA Category 1 Credits: 1.25

Presentations